These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31105049)

  • 1. Universal Correction of Blood Coagulation Factor VIII in Patient-Derived Induced Pluripotent Stem Cells Using CRISPR/Cas9.
    Park CY; Sung JJ; Cho SR; Kim J; Kim DW
    Stem Cell Reports; 2019 Jun; 12(6):1242-1249. PubMed ID: 31105049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs.
    Sung JJ; Park CY; Leem JW; Cho MS; Kim DW
    Exp Mol Med; 2019 Apr; 51(4):1-9. PubMed ID: 30996250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a gene edited hemophilia A patient-derived iPSC cell line, YCMi001-B-1, by targeted insertion of coagulation factor FVIII using CRISPR/Cas9.
    Sung JJ; Park S; Choi SH; Kim J; Cho MS; Kim DW
    Stem Cell Res; 2020 Oct; 48():101948. PubMed ID: 32798916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using CRISPR-Cas9.
    Park CY; Kim DH; Son JS; Sung JJ; Lee J; Bae S; Kim JH; Kim DW; Kim JS
    Cell Stem Cell; 2015 Aug; 17(2):213-20. PubMed ID: 26212079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic correction of hemophilia A using 2D endothelial cells and multicellular 3D organoids derived from CRISPR/Cas9-engineered patient iPSCs.
    Son JS; Park CY; Lee G; Park JY; Kim HJ; Kim G; Chi KY; Woo DH; Han C; Kim SK; Park HJ; Kim DW; Kim JH
    Biomaterials; 2022 Apr; 283():121429. PubMed ID: 35217482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling of hemophilia A using patient-specific induced pluripotent stem cells derived from urine cells.
    Jia B; Chen S; Zhao Z; Liu P; Cai J; Qin D; Du J; Wu C; Chen Q; Cai X; Zhang H; Yu Y; Pei D; Zhong M; Pan G
    Life Sci; 2014 Jul; 108(1):22-9. PubMed ID: 24834837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs.
    Park CY; Kim J; Kweon J; Son JS; Lee JS; Yoo JE; Cho SR; Kim JH; Kim JS; Kim DW
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9253-8. PubMed ID: 24927536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.
    Morishige S; Mizuno S; Ozawa H; Nakamura T; Mazahery A; Nomura K; Seki R; Mouri F; Osaki K; Yamamura K; Okamura T; Nagafuji K
    Int J Hematol; 2020 Feb; 111(2):225-233. PubMed ID: 31664646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ectopic Expression of FVIII in HPCs and MSCs Derived from hiPSCs with Site-Specific Integration of
    Zhao J; Zhou M; Wang Z; Wu L; Hu Z; Liang D
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of the human F8 at the multicopy rDNA locus in Hemophilia A patient-derived iPSCs using TALENickases.
    Pang J; Wu Y; Li Z; Hu Z; Wang X; Hu X; Wang X; Liu X; Zhou M; Liu B; Wang Y; Feng M; Liang D
    Biochem Biophys Res Commun; 2016 Mar; 472(1):144-9. PubMed ID: 26921444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA base editing corrects common hemophilia A mutations and restores factor VIII expression in in vitro and ex vivo models.
    Tonetto E; Cucci A; Follenzi A; Bernardi F; Pinotti M; Balestra D
    J Thromb Haemost; 2024 Aug; 22(8):2171-2183. PubMed ID: 38718928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted genome engineering based on CRISPR/Cas9 system to enhance FVIII expression in vitro.
    Zhao L; Fang S; Ma Y; Ren J; Hao L; Wang L; Yang J; Lu X; Yang L; Wang G
    Gene; 2024 Feb; 896():148038. PubMed ID: 38036077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs.
    Wu Y; Hu Z; Li Z; Pang J; Feng M; Hu X; Wang X; Lin-Peng S; Liu B; Chen F; Wu L; Liang D
    Sci Rep; 2016 Jan; 6():18865. PubMed ID: 26743572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system.
    Wattanapanitch M; Damkham N; Potirat P; Trakarnsanga K; Janan M; U-Pratya Y; Kheolamai P; Klincumhom N; Issaragrisil S
    Stem Cell Res Ther; 2018 Feb; 9(1):46. PubMed ID: 29482624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII.
    Chen H; Shi M; Gilam A; Zheng Q; Zhang Y; Afrikanova I; Li J; Gluzman Z; Jiang R; Kong LJ; Chen-Tsai RY
    Sci Rep; 2019 Nov; 9(1):16838. PubMed ID: 31727959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream.
    Neumeyer J; Lin RZ; Wang K; Hong X; Hua T; Croteau SE; Neufeld EJ; Melero-Martin JM
    Blood Adv; 2019 Dec; 3(24):4166-4176. PubMed ID: 31851760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration.
    Burnight ER; Gupta M; Wiley LA; Anfinson KR; Tran A; Triboulet R; Hoffmann JM; Klaahsen DL; Andorf JL; Jiao C; Sohn EH; Adur MK; Ross JW; Mullins RF; Daley GQ; Schlaeger TM; Stone EM; Tucker BA
    Mol Ther; 2017 Sep; 25(9):1999-2013. PubMed ID: 28619647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing.
    Nakamura T; Morishige S; Ozawa H; Kuboyama K; Yamasaki Y; Oya S; Yamaguchi M; Aoyama K; Seki R; Mouri F; Osaki K; Okamura T; Mizuno S; Nagafuji K
    Haemophilia; 2020 Sep; 26(5):826-833. PubMed ID: 32700411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A.
    Olgasi C; Talmon M; Merlin S; Cucci A; Richaud-Patin Y; Ranaldo G; Colangelo D; Di Scipio F; Berta GN; Borsotti C; Valeri F; Faraldi F; Prat M; Messina M; Schinco P; Lombardo A; Raya A; Follenzi A
    Stem Cell Reports; 2018 Dec; 11(6):1391-1406. PubMed ID: 30416049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.